home / stock / goss / goss quote
Last: | $ |
---|---|
Change Percent: | 1.20% |
Open: | $15.02 |
Close: | $15.21 |
High: | $15.22 |
Low: | $14.79 |
Volume: | 313,154 |
Last Trade Date Time: | 02/12/2020 04:40:17 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $15.02 | $15.21 | $15.22 | $14.79 | 313,154 | 02-12-2020 |
$ | $15.16 | $15.03 | $15.29 | $14.8401 | 393,304 | 02-11-2020 |
$ | $14.91 | $15.14 | $15.29 | $14.70 | 329,741 | 02-10-2020 |
$ | $14.62 | $14.80 | $14.83 | $14.25 | 288,892 | 02-07-2020 |
$ | $14.84 | $14.62 | $14.894 | $14.43 | 288,729 | 02-06-2020 |
$ | $13.89 | $14.67 | $14.93 | $13.78 | 399,976 | 02-05-2020 |
$ | $13.66 | $13.84 | $14.05 | $13.51 | 243,088 | 02-04-2020 |
$ | $13.39 | $13.64 | $13.97 | $13.34 | 378,330 | 02-03-2020 |
$ | $13.50 | $13.28 | $13.56 | $13.15 | 333,384 | 01-31-2020 |
$ | $13.58 | $13.53 | $13.90 | $13.30 | 315,292 | 01-30-2020 |
$ | $13.95 | $13.68 | $14.07 | $13.435 | 383,163 | 01-29-2020 |
$ | $14.02 | $13.93 | $14.12 | $13.53 | 359,105 | 01-28-2020 |
$ | $13.45 | $13.89 | $14.09 | $13.13 | 512,646 | 01-27-2020 |
$ | $13.42 | $13.33 | $13.855 | $13.15 | 630,975 | 01-24-2020 |
$ | $13.99 | $13.37 | $14.00 | $13.17 | 910,401 | 01-23-2020 |
$ | $14.06 | $13.46 | $14.18 | $13.31 | 366,518 | 01-22-2020 |
$ | $14.22 | $13.97 | $14.5565 | $13.88 | 475,788 | 01-21-2020 |
$ | $15.15 | $14.34 | $15.26 | $14.34 | 238,966 | 01-20-2020 |
$ | $15.15 | $14.34 | $15.26 | $14.34 | 238,879 | 01-17-2020 |
$ | $15.16 | $15.00 | $15.47 | $14.7908 | 557,212 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
2024-03-20 10:20:00 ET March 20, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech/Life Sciences sector. The newest biotech companies are involved in immuno-oncology, ...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced...
- First PAH Patient Dosed in Ongoing Registrational Phase 3 PROSERA Study - - Inclusion of Japan in Phase 3 PROSERA Study Following CTN Acceptance by PMDA - - Cash, cash equivalents and marketable securities totaled $296 million at year-end 2023 - Gossamer Bio, Inc. (Nas...